iRadimed Corporation $IRMD is Bridge City Capital LLC’s 7th Largest Position

Bridge City Capital LLC grew its holdings in iRadimed Corporation (NASDAQ:IRMD) by 19.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 70,854 shares of the medical equipment provider’s stock after purchasing an additional 11,509 shares during the quarter. iRadimed accounts for about 2.0% of Bridge City Capital LLC’s holdings, making the stock its 7th biggest holding. Bridge City Capital LLC owned about 0.56% of iRadimed worth $6,893,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL purchased a new position in iRadimed in the third quarter worth approximately $666,000. SG Americas Securities LLC lifted its stake in iRadimed by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock worth $6,848,000 after acquiring an additional 33,072 shares during the last quarter. Principal Financial Group Inc. purchased a new position in iRadimed in the third quarter worth approximately $422,000. RFG Advisory LLC purchased a new position in iRadimed in the fourth quarter worth approximately $1,594,000. Finally, Baader Bank Aktiengesellschaft purchased a new position in iRadimed in the fourth quarter worth approximately $595,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Stock Down 2.8%

Shares of iRadimed stock opened at $93.60 on Friday. iRadimed Corporation has a 52-week low of $55.11 and a 52-week high of $107.90. The company has a 50 day moving average of $90.89 and a 200 day moving average of $95.87. The company has a market capitalization of $1.20 billion, a P/E ratio of 51.15 and a beta of 0.91.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The company had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, research analysts anticipate that iRadimed Corporation will post 1.52 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Friday, May 15th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is presently 43.72%.

Insiders Place Their Bets

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the sale, the chief executive officer owned 2,162,500 shares of the company’s stock, valued at approximately $195,922,500. This trade represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 62,500 shares of company stock worth $5,794,878 over the last 90 days. 36.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

IRMD has been the subject of a number of recent research reports. Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Weiss Ratings downgraded shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $120.00.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.